New treatment to protect brain cells during a stroke
Official title: Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke
Funded at Celdara Medical, LLC · NIH-10932426 · Data updated 2026-11-12
This study is testing a new treatment that aims to protect brain cells during a stroke, which could help improve recovery and reduce long-term disability for stroke patients.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Celdara Medical, LLC NIH-funded |
| Lab location | 1 site (Lebanon, United States) |
| Project start | September 20, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $421,106 |
| NIH project number | 5R43NS127620-02 |
| Project ID | NIH-10932426 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing an acute ischemic stroke who are within the therapeutic time window for treatment.
✕Less likely to help
Patients who have already suffered irreversible brain damage or are outside the treatment window may not benefit from this research.
What this research studies
This research focuses on developing a novel neuroprotective therapy aimed at preserving brain cells during an acute ischemic stroke (AIS). The approach involves targeting a specific signaling pathway that leads to neuronal cell death, with the goal of preventing damage in the brain's ischemic penumbra, the area surrounding the stroke-affected region. The lead compound, CM-EA1, is designed to be administered alongside existing treatments like alteplase, potentially improving outcomes for stroke patients. By enhancing the preservation of brain tissue, this therapy could significantly reduce long-term disability associated with strokes.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that minimizes brain damage and improves recovery for stroke patients.
How similar studies have gone: While the approach of targeting neuronal cell death pathways is promising, it is relatively novel and has not been extensively tested in human trials for stroke treatment.
Where this research is happening
-
Celdara Medical, LLC
Lebanon, United States Active
Researchers
- Principal investigator: Coleman, Julie H — Celdara Medical, LLC
- Study coordinator: Coleman, Julie H
Related research
Other NIH-funded projects on the same topics.
-
Targeted nanomedicine to protect the brain after stroke
A targeted drug-delivery approach aims to boost blood-brain barrier repair and reduce brain damage after an acute ischemic stroke in patients at risk.
-
Modeling Acute Ischemic Stroke to Improve Mechanical Thrombectomy
A research project is creating better computer models and animal studies to help remove clots more safely and effectively in people who have an acute ischemic stroke.
-
Nanoparticle-delivered tPA to overcome clot resistance in acute ischemic stroke
A Mayo Clinic team is testing a nanoparticle-delivered tPA approach to help dissolve clots more effectively in people with acute ischemic stroke due to large vessel blockage.
-
Engineered tissue regulatory T cells as a treatment for stroke
A new off-the-shelf cell therapy using engineered regulatory T cells could help people who have an ischemic stroke recover by reducing inflammation and promoting tissue repair.
-
Fast penumbral imaging to guide stroke treatment
Aims to develop quick MRI techniques to identify tissue at risk in acute ischemic stroke and help decide whether to use advanced clot-busting treatment.
-
Circadian factors shaping reperfusion success in acute stroke
This grant looks at how the body’s internal clock might influence how well stroke patients respond to clot-busting or clot-removal treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.